scholarly journals The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

Endocrine ◽  
2019 ◽  
Vol 64 (3) ◽  
pp. 657-672 ◽  
Author(s):  
Rosario Pivonello ◽  
Giorgio Arnaldi ◽  
Carla Scaroni ◽  
Carla Giordano ◽  
Salvo Cannavò ◽  
...  
Keyword(s):  
Medical Treatment ◽  
Real World ◽  
Cushing’S Disease ◽  
Cushing's Disease ◽  
Real World Evidence

scholarly journals Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study

Pituitary ◽  
2019 ◽  
Vol 22 (5) ◽  
pp. 542-551 ◽  
Author(s):  
Luca Manetti ◽  
Timo Deutschbein ◽  
Jochen Schopohl ◽  
Kevin C. J. Yuen ◽  
Michael Roughton ◽  
...  
Keyword(s):  
Real World ◽  
Cushing’S Disease ◽  
Cushing's Disease ◽  
Safety And Efficacy ◽  
Real World Evidence

Presurgical medical treatment in Cushing's disease

2017 ◽  
Author(s):  
Paloma Moreno-Moreno ◽  
Ana Barrera-Martin ◽  
Alejandro Ibanez-Costa ◽  
Maria Rosa Alhambra-Exposito ◽  
Concepcion Munoz-Jimenez ◽  
...  
Keyword(s):  
Medical Treatment ◽  
Cushing’S Disease ◽  
Cushing's Disease

Pituitary-directed medical treatment of Cushing’s disease

2009 ◽  
Vol 4 (3) ◽  
pp. 263-272
Author(s):  
Giorgio Arnaldi ◽  
Marina Cardinaletti ◽  
Laura Trementino ◽  
Giacomo Tirabassi ◽  
Marco Boscaro
Keyword(s):  
Medical Treatment ◽  
Cushing’S Disease ◽  
Cushing's Disease

scholarly journals The Medical Treatment of Cushing’s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery

2009 ◽  
Vol 94 (1) ◽  
pp. 223-230 ◽  
Author(s):  
Rosario Pivonello ◽  
Maria Cristina De Martino ◽  
Paolo Cappabianca ◽  
Monica De Leo ◽  
Antongiulio Faggiano ◽  
...  
Keyword(s):  
Medical Treatment ◽  
Dopamine Agonist ◽  
Cushing’S Disease ◽  
Chronic Treatment ◽  
Cushing's Disease

scholarly journals Radiotherapy as a tool for the treatment of Cushing’s disease

2019 ◽  
Vol 180 (5) ◽  
pp. D9-D18 ◽  
Author(s):  
Frederic Castinetti ◽  
Thierry Brue ◽  
Oskar Ragnarsson
Keyword(s):  
Medical Treatment ◽  
Cushing’S Disease ◽  
Pituitary Surgery ◽  
Bilateral Adrenalectomy ◽  
Cushing's Disease ◽  
Limiting Factor ◽  
Pituitary Insufficiency ◽  
Line Treatment ◽  
Second Line ◽  
High Prevalence

Treatment of Cushing’s disease (CD) is one of the most challenging tasks in endocrinology. The first-line treatment, transsphenoidal pituitary surgery, is associated with a high failure rate and a high prevalence of recurrence. Re-operation is associated with an even higher rate of a failure and recurrence. There are three main second-line treatments for CD – pituitary radiation therapy (RT), bilateral adrenalectomy and chronic cortisol-lowering medical treatment. All these treatments have their limitations. While bilateral adrenalectomy provides permanent cure of the hypercortisolism in all patients, the unavoidable chronic adrenal insufficiency and the risk of development of Nelson syndrome are of concern. Chronic cortisol-lowering medical treatment is not efficient in all patients and side effects are often a limiting factor. RT is efficient for approximately two-thirds of all patients with CD. However, the high prevalence of pituitary insufficiency is of concern as well as potential optic nerve damage, development of cerebrovascular disease and secondary brain tumours. Thus, when it comes to decide appropriate treatment for patients with CD, who have either failed to achieve remission with pituitary surgery, or patients with recurrence, the pros and cons of all second-line treatment options must be considered.

Sign in / Sign up

Export Citation Format

Share Document